SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-24-000082
Filing Date
2024-01-05
Accepted
2024-01-05 08:00:18
Documents
14
Period of Report
2024-01-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_010524.htm   iXBRL 8-K 16663
2 PRESS RELEASE exh_991.htm EX-99.1 11015
  Complete submission text file 0001171843-24-000082.txt   233320

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3003
4 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25598
5 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 34011
6 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 22139
8 EXTRACTED XBRL INSTANCE DOCUMENT f8k_010524_htm.xml XML 3125
Mailing Address 80 GUEST STREET BOSTON MA 02135
Business Address 80 GUEST STREET BOSTON MA 02135 617-500-8099
Compass Therapeutics, Inc. (Filer) CIK: 0001738021 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39696 | Film No.: 24514462
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)